Comparison of Disease Activity in SPMS and PPMS in the Context of Multicenter Clinical Trials

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Orbach, Rotem ^a,b   Zhao, Zhenming ^a   Wang, Yong Cheng ^a   O'Neill, Gilmore ^a   Cadavid, Diego ^a  

^a BIOGEN   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DEMYELINATING DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; FEMALE; GENE EXPRESSION PROFILING; GENERAL CONDITION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PHENOTYPIC VARIATION; PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS; QUALITY OF LIFE;

CLUSTER ANALYSIS; DISEASE PROGRESSION; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PLACEBOS; QUALITY OF LIFE; TIME FACTORS;

EID: 84867025308     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045409     Document Type: Article

References (28)

1. Lublin FD, Reingold SC, (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46: 907-911.
2. Ebers G, Heigehauser L, Daumer M, Lederer C, Noseworthy J, (2008) Disability as an outcome in MS clinical Trials. Neurology 71: 624-631.
3. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, et al. (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112 (Pt 6): 1419-1428.
4. Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC, (2009) Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol 5: 672-682.
5. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, et al. (2010) The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133: 1914-1929.
6. Confavreux C, Vukusic S, (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129: 606-616.
7. Confavreux C, Vukusic S, Moreau T, Adeleine P, (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343: 1430-1438.
8. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, et al. (2002) Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59: 679-687.
9. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460-471.
10. Lex A, Streit M, Partl C, Kashofer K, Schmalstieg D, (2010) Comparative analysis of multidimensional, quantitative data. IEEE Trans Vis Comput Graph 16: 1027-1035.
11. Kurtzke JF, (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
12. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, et al. (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122 (Pt 5): 871-882.
13. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, et al. (1999) Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 5: 251-259.
14. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, et al. (2006) Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 5: 343-354.
15. Lassmann H, (2007) New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep 7: 239-244.
16. Siepman TA, Bettink-Remeijer MW, Hintzen RQ, (2010) Retinal nerve fiber layer thickness in subgroups of multiple sclerosis, measured by optical coherence tomography and scanning laser polarimetry. J Neurol 257: 1654-1660.
17. Quintana FJ, Farez MF, Viglietta V, Iglesias AH, Merbl Y, et al. (2008) Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A 105: 18889-18894.
18. Villar LM, Masterman T, Casanova B, Gomez-Rial J, Espino M, et al. (2009) CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. J Neuroimmunol 211: 101-104.
19. Stevenson VL, Miller DH, Leary SM, Rovaris M, Barkhof F, et al. (2000) One year follow up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 68: 713-718.
20. Stevenson VL, Smith SM, Matthews PM, Miller DH, Thompson AJ, (2002) Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy. J Neurol 249: 171-177.
21. Amato MP, Grimaud J, Achiti I, Bartolozzi ML, Adeleine P, et al. (2004) European validation of a standardized clinical description of multiple sclerosis. J Neurol 251: 1472-1480.
22. Polman CH, Rudick RA, (2010) The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology 74Suppl 3: S8-15.
23. Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, et al. (2007) Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61: 14-24.
24. Hawker K, O'Connor P, Freedman M, Calabresi P, J A, et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology 66: 460-471.
25. Kragt JJ, Thompson AJ, Montalban X, Tintore M, Rio J, et al. (2008) Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology 70: 1084-1091.
26. Cadavid D, Tang Y, O'Neill G, (2010) [Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis]. Rev Neurol 51: 321-329.
27. La Mantia L, Vacchi L, Di Pietrantonj C, Ebers G, Rovaris M, et al. (2012) Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev 1: CD005181.
28. Rudick R, Polman C, Cohen J, Walton M, Miller A, et al. (2009) Assessing disability progression with the Multiple Sclerosis Functional Composite. Multiple Sclerosis 15: 984-997.